A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
A phase 2 trial of Oregovomab, Niraparib in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
Overview
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT05335993 by CanariaBio Inc., with 10 participants enrolled, started 2022-07-25 and due to reach its primary completion in 2026-12-30. Interventions recorded: Oregovomab, Niraparib. Conditions listed: Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Shares Oregovomab, Ovarian cancer.
- TrialOregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Shares Oregovomab, Ovarian cancer.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Oregovomab, Ovarian cancer.
- TrialA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Shares Niraparib, Ovarian cancer.
- TrialA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Shares Niraparib, Ovarian cancer.
- TrialPhase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat
Shares Niraparib, Ovarian cancer.
- PersonAmit M. Oza
Shares Niraparib, Ovarian cancer.
- IdeactDNA-guided duration of PARP maintenance
Shares Niraparib, Ovarian cancer.